MedTrace Logo

Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial Pneumonia

NCT02728518 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2016-08-25

No results posted yet for this study

Summary

The investigator's goal in this study is to evaluate the efficacy and safety of nebulized amikacin versus intravenous amikacin in patients with hospital and ventilator acquired pneumonia in surgical patients admitted to the intensive care units infected with gram negative bacilli

Conditions

Interventions

DRUG

Nebulized Amikacin

400mg twice daily nebulized amikacin

DRUG

Intravenous Amikacin

20mg/kg once daily intravenous amikacin

Sponsors & Collaborators

  • National Heart Institute, Egypt

    lead OTHER_GOV

Principal Investigators

  • Nehal A Hassan, BCPS · National Heart Institute

  • Faten F El sayed, MD · National Heart Institute

  • Nirmeen A Sabry, Ph.D · Faculty of Pharmacy Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-08-31
Completion
2015-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02728518 on ClinicalTrials.gov